MARKET

CDNA

CDNA

Caredx
NASDAQ
7.98
-0.25
-3.04%
After Hours: 7.98 0 0.00% 16:22 04/24 EDT
OPEN
8.20
PREV CLOSE
8.23
HIGH
8.37
LOW
7.96
VOLUME
519.51K
TURNOVER
0
52 WEEK HIGH
12.93
52 WEEK LOW
4.800
MARKET CAP
413.19M
P/E (TTM)
-2.2547
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CDNA last week (0415-0419)?
Weekly Report · 2d ago
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
CareDx granted an option to purchase 700,706 shares of CareDx’s common stock to John Hanna on April 15, 2024. The Transplant Company is a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers.
Barchart · 5d ago
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
NASDAQ · 6d ago
CareDx Price Target Maintained With a $15.00/Share by Stephens & Co.
Dow Jones · 04/17 14:21
Stephens & Co. Reiterates Overweight on CareDx, Maintains $15 Price Target
Benzinga · 04/17 14:11
CareDx Appoints John W. Hanna as New CEO and Board Member
TipRanks · 04/16 20:32
CareDx Name John Hanna as Chief Executive
John Hanna previously served as CEO of Apton Biosystems. CareDx named John Hanna as its new president and chief executive, effective April 15. The company has been looking for a new CEO since November. Hanna replaces Reginald Seeto, who stepped down.
Dow Jones · 04/16 20:19
CareDx appoints John Hanna as president and CEO
Seeking Alpha · 04/16 20:07
More
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.

Webull offers CareDx Inc stock information, including NASDAQ: CDNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDNA stock methods without spending real money on the virtual paper trading platform.